Ascendis Pharma A/S (NASDAQ:ASND) – Analysts at Wedbush decreased their Q2 2017 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research report issued on Wednesday. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will post earnings per share of ($0.82) for the quarter, down from their prior estimate of ($0.74). Wedbush currently has a “Outperform” rating and a $34.00 target price on the stock. Wedbush also issued estimates for Ascendis Pharma A/S’s Q3 2017 earnings at ($0.82) EPS, Q4 2017 earnings at ($0.83) EPS, FY2017 earnings at ($3.32) EPS, Q1 2018 earnings at ($0.83) EPS, Q2 2018 earnings at ($0.84) EPS, Q3 2018 earnings at ($0.85) EPS, Q4 2018 earnings at ($0.87) EPS, FY2018 earnings at ($3.39) EPS, FY2019 earnings at ($4.32) EPS, FY2020 earnings at ($3.43) EPS and FY2021 earnings at ($0.43) EPS.
Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Tuesday, May 23rd. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.19. The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $1.10 million. Ascendis Pharma A/S had a negative return on equity of 65.92% and a negative net margin of 1,158.57%. WARNING: This story was originally posted by BBNS and is the property of of BBNS. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://baseballnewssource.com/markets/ascendis-pharma-as-to-post-q2-2017-earnings-of-0-82-per-share-wedbush-forecasts-asnd-updated-updated/862391.html.
A number of other analysts have also commented on the company. ValuEngine raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Saturday. Leerink Swann decreased their price objective on Ascendis Pharma A/S from $30.00 to $26.00 and set a “market perform” rating for the company in a report on Thursday. Zacks Investment Research raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday. JPMorgan Chase & Co. initiated coverage on Ascendis Pharma A/S in a research note on Thursday, May 11th. They issued an “overweight” rating and a $36.00 target price on the stock. Finally, Credit Suisse Group AG initiated coverage on Ascendis Pharma A/S in a research note on Thursday, February 9th. They issued an “outperform” rating and a $28.00 target price on the stock. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $29.60.
Ascendis Pharma A/S (NASDAQ:ASND) opened at 24.23 on Friday. The stock’s 50 day moving average price is $27.66 and its 200 day moving average price is $24.61. Ascendis Pharma A/S has a 52-week low of $11.92 and a 52-week high of $31.86. The firm’s market capitalization is $787.52 million.
A number of large investors have recently modified their holdings of the stock. Victory Capital Management Inc. purchased a new position in Ascendis Pharma A/S during the first quarter valued at $144,000. Karp Capital Management Corp purchased a new position in Ascendis Pharma A/S during the first quarter valued at $203,000. Highbridge Capital Management LLC purchased a new position in Ascendis Pharma A/S during the fourth quarter valued at $405,000. EcoR1 Capital LLC boosted its position in Ascendis Pharma A/S by 345.1% in the fourth quarter. EcoR1 Capital LLC now owns 975,700 shares of the biotechnology company’s stock valued at $19,748,000 after buying an additional 756,500 shares during the last quarter. Finally, Deerfield Management Co. purchased a new position in Ascendis Pharma A/S during the fourth quarter valued at $21,252,000. 44.51% of the stock is currently owned by institutional investors and hedge funds.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with our FREE daily email newsletter.